BioSpace News Archive

Eli Lilly and Company announced its financial results for the second quarter of 2022.

Bio-Teche Corporation announced Chuck Kummeth’s planned two-year transition from his position as Bio-Techne’s Chief Executive Officer effective June 30, 2024.

Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2022.

BD, a leading global medical technology company, announced results for its third quarter of fiscal year 2022, which ended June 30, 2022.

NanoViricides, Inc., a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus.

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations, who have human epidermal growth factor receptor 2 -negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

RVL Pharmaceuticals plc, a specialty pharmaceutical company focused on the commercialization of UPNEEQ®, 0.1%, announced that the Company will release its second quarter 2022 financial results and provide a commercial update on Thursday, August 11, 2022, before U.S. financial markets open.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced its second-quarter 2022 financial results.

Ginkgo Bioworks, the leading horizontal platform for cell programming, announced that Kathy Hopinkah Hannan, PhD, CPA has joined its Board of Directors, effective August 2, 2022.

Zoetis Inc. reported its financial results for the second quarter of 2022 and updated its guidance for full year 2022 to reflect its positive outlook for the remainder of the year, as well as the negative impact of recent changes to foreign exchange rates.